Jefferies on CytomX Therapeutics (CTMX): 'we see good entry point at current value' amid Vareseta-M derisking
Tweet Send to a Friend
Jefferies analyst Roger Song reiterated a Buy rating and $16.00 price target on CytomX Therapeutics (NASDAQ: CTMX)The analyst commented, "We ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
